Mecox Curemed Accelerates Entry into US Market... Establishes Local Corporation 'Mecox Medi'

[Asia Economy Reporter Jang Hyowon] New drug development company Mecox Cure Med is intensifying its entry into the U.S. market.

Mecox Cure Med announced on the 21st that it has incorporated its local subsidiary 'Mecox Medi,' established for entry into the North American market, as a subsidiary. 'Mecox Medi' plans to focus on ▲building infrastructure for overseas market entry of Mecox Cure Med's major pipelines ▲listing on the U.S. Nasdaq ▲attracting overseas investment.

For efficient operations, Mecox Cure Med will promote its COVID-19 treatment 'M002-A,' arthritis treatment 'Bozanics,' and anticancer drug 'Mecbentu' in the U.S. market through its subsidiary 'Mecox Medi.'

A Mecox Cure Med official stated, “In collaboration with Black Canyon Capital, which proposed comprehensive consulting including Nasdaq listing through Mecox Medi, we plan to start with external funding investment and prioritize registration on the U.S. OTC market. The local investment and consulting expert group recognizes Mecox Cure Med's technology and has actively requested proposals, laying the foundation for entry into the U.S. market. We will carefully review various possibilities and pursue business diversification.”

Meanwhile, Mecox Cure Med signed a consulting contract with the global securities market expert group Black Canyon Capital last October, establishing a foothold for Nasdaq entry. Black Canyon Capital is known as an investment and consulting expert group that has helped numerous companies enter the U.S. securities markets (NYSE, NASDAQ, OTCQX, OTCQB, PINKSHEET).

This content was produced with the assistance of AI translation services.